In parallel, METTL1‐catalyzed m7G modification of tRNA contributes to lenvatinib resistance in HCC by selectively elevating TE of genes within the EGFR signalling, thereby sustaining oncogenic signalling and chemoresistance.76 This evidence concerns the gene METTL1 and hepatocellular carcinoma.